HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
To the Editor: Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 ( HER2 ) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer. 1 Initial trials enrolled patients wit...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2008-03, Vol.358 (13), p.1409-1411 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1411 |
|---|---|
| container_issue | 13 |
| container_start_page | 1409 |
| container_title | The New England journal of medicine |
| container_volume | 358 |
| creator | Paik, Soonmyung Kim, Chungyeul Wolmark, Norman |
| description | To the Editor:
Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 (
HER2
) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer.
1
Initial trials enrolled patients with tumors that had a staining intensity of 2+ or 3+ for HER2 on immunohistochemical analysis, but in subsequent studies, the benefit was limited to tumors with
HER2
amplification as determined by fluorescence in situ hybridization (FISH). Trastuzumab also improves disease-free survival and overall survival in the adjuvant setting.
2
On the basis of its mechanism of action, . . . |
| doi_str_mv | 10.1056/NEJMc0801440 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70437042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70437042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-175b42110cd7d2e29e2839b8b1d83c7273c881dfeba6e79843a2aa4b8a6b7f4b3</originalsourceid><addsrcrecordid>eNpt0M1LwzAYBvAgipvTm2cJIp6s5qtNetzG_GIq6DyHpE2hY0ln0gj61xvZQBEDL0ngx8PLA8AxRpcY5cXV4-z-oUICYcbQDhjinNIsPYtdMESIiIzxkg7AQQhLlA5m5T4YYEELznM8BJPb2TOBL73qY4DK1XBinGnaHja-s3BcL-O7cj1ceBX6-Bmt0rB1cOJN-sOpcpXxh2CvUatgjrb3CLxezxbT22z-dHM3Hc-zigrWZ5jnmhGMUVXzmhhSGiJoqYXGtaAVJ5xWQuC6MVoVhpeCUUWUYlqoQvOGaToC55vcte_eogm9tG2ozGqlnOlikBwxmoYkePoHLrvoXdpNEkJLXLIyT-higyrfheBNI9e-tcp_SIzkd7Hyd7GJn2wzo7am_sHbJhM42wBrg3Rmaf_P-QIhz3vK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223919495</pqid></control><display><type>article</type><title>HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><creator>Paik, Soonmyung ; Kim, Chungyeul ; Wolmark, Norman</creator><creatorcontrib>Paik, Soonmyung ; Kim, Chungyeul ; Wolmark, Norman</creatorcontrib><description>To the Editor:
Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 (
HER2
) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer.
1
Initial trials enrolled patients with tumors that had a staining intensity of 2+ or 3+ for HER2 on immunohistochemical analysis, but in subsequent studies, the benefit was limited to tumors with
HER2
amplification as determined by fluorescence in situ hybridization (FISH). Trastuzumab also improves disease-free survival and overall survival in the adjuvant setting.
2
On the basis of its mechanism of action, . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc0801440</identifier><identifier>PMID: 18367751</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - therapeutic use ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Chemotherapy, Adjuvant ; Female ; Gene Amplification ; Genes, erbB-2 ; Humans ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - immunology ; Receptor, ErbB-2 - metabolism ; RNA, Messenger - metabolism ; Trastuzumab</subject><ispartof>The New England journal of medicine, 2008-03, Vol.358 (13), p.1409-1411</ispartof><rights>Copyright © 2008 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-175b42110cd7d2e29e2839b8b1d83c7273c881dfeba6e79843a2aa4b8a6b7f4b3</citedby><cites>FETCH-LOGICAL-c384t-175b42110cd7d2e29e2839b8b1d83c7273c881dfeba6e79843a2aa4b8a6b7f4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc0801440$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223919495?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18367751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paik, Soonmyung</creatorcontrib><creatorcontrib>Kim, Chungyeul</creatorcontrib><creatorcontrib>Wolmark, Norman</creatorcontrib><title>HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 (
HER2
) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer.
1
Initial trials enrolled patients with tumors that had a staining intensity of 2+ or 3+ for HER2 on immunohistochemical analysis, but in subsequent studies, the benefit was limited to tumors with
HER2
amplification as determined by fluorescence in situ hybridization (FISH). Trastuzumab also improves disease-free survival and overall survival in the adjuvant setting.
2
On the basis of its mechanism of action, . . .</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Chemotherapy, Adjuvant</subject><subject>Female</subject><subject>Gene Amplification</subject><subject>Genes, erbB-2</subject><subject>Humans</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>RNA, Messenger - metabolism</subject><subject>Trastuzumab</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0M1LwzAYBvAgipvTm2cJIp6s5qtNetzG_GIq6DyHpE2hY0ln0gj61xvZQBEDL0ngx8PLA8AxRpcY5cXV4-z-oUICYcbQDhjinNIsPYtdMESIiIzxkg7AQQhLlA5m5T4YYEELznM8BJPb2TOBL73qY4DK1XBinGnaHja-s3BcL-O7cj1ceBX6-Bmt0rB1cOJN-sOpcpXxh2CvUatgjrb3CLxezxbT22z-dHM3Hc-zigrWZ5jnmhGMUVXzmhhSGiJoqYXGtaAVJ5xWQuC6MVoVhpeCUUWUYlqoQvOGaToC55vcte_eogm9tG2ozGqlnOlikBwxmoYkePoHLrvoXdpNEkJLXLIyT-higyrfheBNI9e-tcp_SIzkd7Hyd7GJn2wzo7am_sHbJhM42wBrg3Rmaf_P-QIhz3vK</recordid><startdate>20080327</startdate><enddate>20080327</enddate><creator>Paik, Soonmyung</creator><creator>Kim, Chungyeul</creator><creator>Wolmark, Norman</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20080327</creationdate><title>HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer</title><author>Paik, Soonmyung ; Kim, Chungyeul ; Wolmark, Norman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-175b42110cd7d2e29e2839b8b1d83c7273c881dfeba6e79843a2aa4b8a6b7f4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Chemotherapy, Adjuvant</topic><topic>Female</topic><topic>Gene Amplification</topic><topic>Genes, erbB-2</topic><topic>Humans</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>RNA, Messenger - metabolism</topic><topic>Trastuzumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paik, Soonmyung</creatorcontrib><creatorcontrib>Kim, Chungyeul</creatorcontrib><creatorcontrib>Wolmark, Norman</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paik, Soonmyung</au><au>Kim, Chungyeul</au><au>Wolmark, Norman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2008-03-27</date><risdate>2008</risdate><volume>358</volume><issue>13</issue><spage>1409</spage><epage>1411</epage><pages>1409-1411</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>To the Editor:
Trastuzumab, an antibody against the protein product of the human epidermal growth factor receptor type 2 (
HER2
) gene, improves progression-free survival and overall survival when added to chemotherapy in patients with metastatic breast cancer.
1
Initial trials enrolled patients with tumors that had a staining intensity of 2+ or 3+ for HER2 on immunohistochemical analysis, but in subsequent studies, the benefit was limited to tumors with
HER2
amplification as determined by fluorescence in situ hybridization (FISH). Trastuzumab also improves disease-free survival and overall survival in the adjuvant setting.
2
On the basis of its mechanism of action, . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>18367751</pmid><doi>10.1056/NEJMc0801440</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2008-03, Vol.358 (13), p.1409-1411 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70437042 |
| source | MEDLINE; New England Journal of Medicine Current; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland |
| subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Chemotherapy, Adjuvant Female Gene Amplification Genes, erbB-2 Humans Receptor, ErbB-2 - genetics Receptor, ErbB-2 - immunology Receptor, ErbB-2 - metabolism RNA, Messenger - metabolism Trastuzumab |
| title | HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A41%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2%20Status%20and%20Benefit%20from%20Adjuvant%20Trastuzumab%20in%20Breast%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Paik,%20Soonmyung&rft.date=2008-03-27&rft.volume=358&rft.issue=13&rft.spage=1409&rft.epage=1411&rft.pages=1409-1411&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMc0801440&rft_dat=%3Cproquest_cross%3E70437042%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223919495&rft_id=info:pmid/18367751&rfr_iscdi=true |